Elutia said it expects FDA clearance for its NXT-41x product in the first half of 2027 and reiterated expectations for NXT-41 clearance in the fourth quarter of 2026. The company also announced up to $26 million of additional capital with no equity offering and a definitive agreement to sell SimpliDerm for up to $11 million. Second quarter net sales were $2.4 million, down from $2.7 million a year earlier, while GAAP gross margin improved to 59.6% from 52.9%. Management said it targets gross margins greater than 80% at scale and expects at least $300 million of revenue capacity at launch. A blinded survey of 50 plastic and reconstructive surgeons found 96% expressed interest in adopting NXT-41x and 92% would champion it at their hospital's value analysis committee.
Elutia Inc.FDA clearance expectations for NXT-41x and NXT-41, plus strong surgeon survey interest, signal product progress.
